-+ 0.00%
-+ 0.00%
-+ 0.00%

SSY Group says China regulator approves ziprasidone hydrochloride as bulk drug

PUBT·08/07/2026 09:04:11
Listen to the news
SSY Group says China regulator approves ziprasidone hydrochloride as bulk drug
  • SSY Group secured China NMPA registration approval for ziprasidone hydrochloride as a bulk drug for marketed preparations.
  • The second-generation antipsychotic is used mainly to treat schizophrenia, expanding SSY’s psychotropic and neurological API portfolio.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SSY Group Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260807-12277029), on August 07, 2026, and is solely responsible for the information contained therein.